newsfilter
← Latest News
Business Wire·

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

  • Bruker Corporation launched CellScape™ XR, a next-generation spatial proteomics platform designed to deliver high-throughput, reproducible quantitation & flexibility for clinical translation.
  • The platform addresses translational research bottlenecks by combining highly multiplexed protein detection with improved optics, fluidics, & protocols without compromising spatial resolution.
  • The University Hospital Schleswig-Holstein (UKSH) has analyzed over 1,000 clinically annotated samples using the platform, with plans to extend the study to approximately 3,000 patient samples.
  • UKSH researchers aim to develop AI-informed prognostic signatures across solid tumor indications, citing the platform's quantitative consistency as essential for building clinically meaningful assays.
  • Bruker will present details on CellScape XR & broader innovations at the AGBT 2026 Silver Sponsor Workshop on Wednesday, February 25.
  • The launch reinforces Bruker's commitment to supporting the full spatial proteomics lifecycle from discovery research to diagnostic development.